Found: 21
Select item for more details and to access through your institution.
Comprehensive coagulation and fibrinolytic potential in the acute phase of pediatric patients with idiopathic nephrotic syndrome evaluated by whole blood-based rotational thromboelastometry.
- Published in:
- Pediatric Nephrology, 2022, v. 37, n. 7, p. 1605, doi. 10.1007/s00467-021-05366-4
- By:
- Publication type:
- Article
Screening of the protein C pathway abnormality‐related thrombophilia by using thrombomodulin‐mediated tissue factor‐triggered clot waveform analysis.
- Published in:
- European Journal of Haematology, 2022, v. 109, n. 1, p. 100, doi. 10.1111/ejh.13777
- By:
- Publication type:
- Article
Hybrid human‐porcine factor VIII proteins partially escape the inhibitory effects of anti‐factor VIII inhibitor alloantibodies having A2 or C2 domain specificity.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 140, doi. 10.1111/hae.14911
- By:
- Publication type:
- Article
Coagulation potentials of plasma‐derived factors VIIa and X mixture (Byclot<sup>®</sup>) evaluated by global coagulation assay in patients with acquired haemophilia A.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 249, doi. 10.1111/hae.14902
- By:
- Publication type:
- Article
Intra‐articular haemorrhage caused by reduced recovery of PEGylated recombinant factor VIII due to an anti‐PEG antibody developed after mRNA‐1273 SARS‐CoV‐2 vaccination in haemophilia A.
- Published in:
- Haemophilia, 2023, v. 29, n. 3, p. 935, doi. 10.1111/hae.14786
- By:
- Publication type:
- Article
In vitro evaluation of global coagulation potentials in the co‐presence of plasma‐derived factors Viia/X products (Byclot<sup>®</sup>) and emicizumab in patients with haemophilia A and inhibitors and acquired haemophilia A: A pilot study.
- Published in:
- Haemophilia, 2022, v. 28, n. 5, p. e149, doi. 10.1111/hae.14650
- By:
- Publication type:
- Article
Whole blood ristocetin‐induced platelet impedance aggregometry does not reflect clinical severity in patients with type 1 von Willebrand disease.
- Published in:
- Haemophilia, 2019, v. 25, n. 3, p. e174, doi. 10.1111/hae.13725
- By:
- Publication type:
- Article
Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis‐treated haemophilia A patients with inhibitors.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 5, p. 727, doi. 10.1111/bjh.16574
- By:
- Publication type:
- Article
Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A.
- Published in:
- Pediatric Blood & Cancer, 2023, v. 70, n. 10, p. 1, doi. 10.1002/pbc.30590
- By:
- Publication type:
- Article
Protein C system in preterm babies with chronic lung disease: Prospective study.
- Published in:
- Pediatrics International, 2022, v. 64, n. 1, p. 1, doi. 10.1111/ped.15221
- By:
- Publication type:
- Article
A microchip flow‐chamber assay screens congenital primary hemostasis disorders.
- Published in:
- Pediatrics International, 2021, v. 63, n. 2, p. 160, doi. 10.1111/ped.14378
- By:
- Publication type:
- Article
Emicizumab-mediated hemostatic function assessed by thrombin generation assay in an in vitro model of factor VIII-depleted thrombophilia plasma.
- Published in:
- International Journal of Hematology, 2024, v. 119, n. 2, p. 109, doi. 10.1007/s12185-023-03683-y
- By:
- Publication type:
- Article
Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis.
- Published in:
- International Journal of Hematology, 2023, v. 118, n. 6, p. 690, doi. 10.1007/s12185-023-03667-y
- By:
- Publication type:
- Article
High levels of factor VIII activity in patients with acquired hemophilia A in remission are associated with unusually low coagulation potentials.
- Published in:
- International Journal of Hematology, 2023, v. 117, n. 5, p. 669, doi. 10.1007/s12185-022-03528-0
- By:
- Publication type:
- Article
Two pediatric cases of severe hemophilia A in which emicizumab prophylaxis failed to prevent traumatic extra-articular hemorrhage.
- Published in:
- International Journal of Hematology, 2023, v. 117, n. 4, p. 607, doi. 10.1007/s12185-022-03490-x
- By:
- Publication type:
- Article
A case of a young boy with hyper-fibrinolysis associated with natural fibrin precipitates suspected to have occurred through a novel coagulation and fibrinolysis mechanism.
- Published in:
- 2022
- By:
- Publication type:
- journal article
The balance of comprehensive coagulation and fibrinolytic potential is disrupted in patients with moderate to severe COVID-19.
- Published in:
- International Journal of Hematology, 2022, v. 115, n. 6, p. 826, doi. 10.1007/s12185-022-03308-w
- By:
- Publication type:
- Article
Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients.
- Published in:
- International Journal of Hematology, 2022, v. 115, n. 4, p. 489, doi. 10.1007/s12185-021-03276-7
- By:
- Publication type:
- Article
Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis.
- Published in:
- International Journal of Hematology, 2021, v. 113, n. 6, p. 930, doi. 10.1007/s12185-021-03095-w
- By:
- Publication type:
- Article
Evaluation of clinical severity in patients with type 2N von Willebrand disease using microchip-based flow-chamber system.
- Published in:
- 2020
- By:
- Publication type:
- journal article